Stockreport

Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]

Cartesian Therapeutics, Inc.  (RNAC) 
PDF This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.54 [Read more]